¼¼°èÀÇ ±ÙÁ¢Ä¡·á °èȹ ½Ã½ºÅÛ ½ÃÀå
Brachytherapy Treatment Planning Systems
»óǰÄÚµå : 1777886
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 282 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,180,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,541,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

±ÙÁ¢Ä¡·á °èȹ ½Ã½ºÅÛ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 14¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 8¾ï 8,710¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ±ÙÁ¢Ä¡·á °èȹ ½Ã½ºÅÛ ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 8.3%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 14¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¿ÀÅä ÄÁÅõ¾î¸µ ¼ÒÇÁÆ®¿þ¾î´Â CAGR 9.7%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 6¾ï 8,440¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¸ÖƼ ¸ð´Þ¸®Æ¼ ¼ÒÇÁÆ®¿þ¾î ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 8.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2¾ï 4,170¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR13.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ±ÙÁ¢Ä¡·á °èȹ ½Ã½ºÅÛ ½ÃÀåÀº 2024³â¿¡ 2¾ï 4,170¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â°£ CAGR 13.2%·Î 2030³â±îÁö 3¾ï 1,270¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 4.1%¿Í 8.0%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.6%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ±ÙÁ¢Ä¡·á °èȹ ½Ã½ºÅÛ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

±ÙÁ¢Ä¡·á °èȹ ½Ã½ºÅÛÀ» º¯È­½ÃŰ´Â ±â¼ú Çõ½ÅÀ̶õ?

¾Ï Ä¡·á °èȹ ½Ã½ºÅÛ ½ÃÀåÀº ¾Ï Ä¡·á °èȹÀÇ Á¤È®¼º°ú È¿À²¼ºÀ» À籸ÃàÇÏ´Â ±Þ¼ÓÇÑ ±â¼ú Çõ½ÅÀ¸·Î º¯È­ÀÇ ½Ã±â¸¦ ¸ÂÀÌÇϰí ÀÖ½À´Ï´Ù. °íÇØ»óµµ CT, MRI, PET ½ºÄµÀ» Æ÷ÇÔÇÑ Ã·´Ü ¿µ»ó ±â¼úÀÌ Ä¡·á °èȹ ½Ã½ºÅÛ¿¡ ÅëÇյǾî Á¾¾çÀÇ ÇØºÎÇÐÀû ±¸Á¶ ¹× ÁÖº¯ Á¶Á÷ÀÇ »ó¼¼ÇÑ 3Â÷¿øÀû Ç¥ÇöÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ÀÌ ÅëÇÕÀ» ÅëÇØ º¸´Ù Á¤È®ÇÑ ¼±·® °è»ê°ú °ø°£ ¸ÅÇÎÀÌ °¡´ÉÇØÁ® ¹æ»ç¼º ÀÓÇöõÆ®ÀÇ Ç¥Àû Á¤È®µµ°¡ Çâ»óµË´Ï´Ù. ÷´Ü ÄÄÇ»ÅÍ Áö¿ø ¼³°è(CAD)¿Í ½Ã¹Ä·¹ÀÌ¼Ç ¼ÒÇÁÆ®¿þ¾î¸¦ ÅëÇÕÇÔÀ¸·Î½á ÀÓ»óÀÇ´Â ´Ù¾çÇÑ Ä¡·á ½Ã³ª¸®¿À¸¦ ¸ðµ¨¸µÇÏ°í ¹æ»ç¼± Á¶»ç·®À» ÃÖÀûÈ­ÇÏ¿© °Ç°­ÇÑ Á¶Á÷ ¼Õ»ó À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×À» ÅëÇÑ ¼ÒÇÁÆ®¿þ¾î ¾Ë°í¸®ÁòÀÇ Çõ½ÅÀº º¹ÀâÇÑ °è»êÀÇ ÀÚµ¿È­¸¦ °­È­ÇÏ¿© º¸´Ù ºü¸£°í Á¤È®ÇÑ Ä¡·á °èȹÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ½Ç½Ã°£ µ¥ÀÌÅÍ ÅëÇÕ ¹× ÀûÀÀÁõ °èȹ µµ±¸¸¦ ÅëÇØ Ä¡·á Áß µ¿Àû Á¶Á¤ÀÌ °¡´ÉÇÏ¿© Á¾¾çÀÇ ¸ð¾çÀÌ º¯ÇÏ´õ¶óµµ ÃÖÀûÀÇ Ä¡·á¸¦ À¯ÁöÇÒ ¼ö ÀÖ½À´Ï´Ù. Çâ»óµÈ »ç¿ëÀÚ ÀÎÅÍÆäÀ̽º¿Í ½Ã°¢È­ µµ±¸´Â Á÷°üÀûÀÎ Á¶ÀÛ°ú Á¾ÇÕÀûÀÎ Ä¡·á µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© ´õ ³ªÀº ÀÇ»ç°áÁ¤°ú °£¼ÒÈ­µÈ ¿öÅ©Ç÷ο츦 ÃËÁøÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº È®Àå °¡´ÉÇÑ Ã³¸® ´É·Â°ú ¾ÈÀüÇÑ µ¥ÀÌÅÍ ÀúÀåÀ» Á¦°øÇϴ Ŭ¶ó¿ìµå ±â¹Ý Ç÷§Æû¿¡ ÀÇÇØ µÞ¹ÞħµÇ°í ÀÖÀ¸¸ç, ´ÙÇÐÁ¦ ÆÀ °£ÀÇ °øµ¿ Ä¡·á °èȹÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. Ä¡·á °èȹ ½Ã½ºÅÛÀÌ °è¼Ó ÁøÈ­ÇÏ´Â °¡¿îµ¥, ¿¹Ãø ºÐ¼®°ú µðÁöÅÐ Æ®À©ÀÇ µµÀÔÀ¸·Î ¼±·® ÃøÁ¤ÀÌ ´õ¿í ÃÖÀûÈ­µÇ¾î °³ÀÎ ¸ÂÃãÇü ¾Ï Ä¡·áÀÇ »õ·Î¿î º¥Ä¡¸¶Å©¸¦ È®¸³Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú ¹ßÀüÀº Ä¡·á È¿°ú¿Í ȯÀÚ ¾ÈÀü¼ºÀ» Å©°Ô Çâ»ó½ÃÄÑ Â÷¼¼´ë ºê¶óŰÅ×¶óÇÇ ¼Ö·ç¼ÇÀÇ ±â¹ÝÀ» ¸¶·ÃÇϰí ÀÖ½À´Ï´Ù.

ÀÓ»ó Àû¿ë ¹× ÃÖÁ¾ »ç¿ëÀÚÀÇ ¿ä±¸´Â ¾î¶»°Ô ±ÙÁ¢Ä¡·á °èȹ ½Ã½ºÅÛ ½ÃÀåÀ» Çü¼ºÇϰí Àִ°¡?

ÀÓ»ó Àû¿ë°ú ÃÖÁ¾ »ç¿ëÀÚÀÇ ¿ä±¸»çÇ×ÀÇ ÁøÈ­´Â Àü ¼¼°è Á¾¾ç ¼¾ÅÍ¿¡¼­ ±ÙÁ¢Ä¡·á °èȹ ½Ã½ºÅÛÀÇ È®ÀåÀ» ±Ùº»ÀûÀ¸·Î ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Àü¸³¼±¾Ï, ÀڱðæºÎ¾Ï, À¯¹æ¾Ï Ä¡·á¿¡ ºê¶óŰÅ×¶óÇǰ¡ µµÀԵǸ鼭 ȯÀÚ °³°³ÀÎÀÇ ÇØºÎÇÐÀû ±¸Á¶¿Í Á¾¾çÀÇ Æ¯¼º¿¡ µû¶ó Á¤¹ÐÇÏ°í ¸ÂÃãÈ­µÈ Ä¡·á °èȹÀ» Á¦°øÇÒ ¼ö ÀÖ´Â ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÓ»óÀÇ´Â Á¤È®ÇÑ ¼±·® °è»êÀ» Á¦°øÇÒ »Ó¸¸ ¾Æ´Ï¶ó Ä¡·á Áß ½Ç½Ã°£ Á¶Á¤À» ¿ëÀÌÇÏ°Ô Çϱâ À§ÇØ ¿µ»ó ó¸® ½Ã½ºÅÛ ¹× Á¶»ç ½Ã½ºÅÛ°ú ¿øÈ°ÇÏ°Ô ÅëÇÕµÈ µµ±¸°¡ ÇÊ¿äÇÕ´Ï´Ù. ȯÀÚ ¿¹ÈÄ °³¼±ÀÇ Çʿ伺¿¡ µû¶ó º´¿ø°ú ¾Ï¼¾ÅÍ´Â ¹æ»ç¼± Á¶»çÀÇ Á¤È®µµ¸¦ ³ôÀ̸鼭 Ä¡·á °èȹ ½Ã°£À» ´ÜÃàÇÏ´Â °íµµÈ­µÈ °èȹ ½Ã½ºÅÛ¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ¹æ»ç¼±Á¾¾çÇÐÀÚ, ÀÇÇй°¸®ÇÐÀÚ, ¼±·®ÃøÁ¤ ÀÇ»çµéÀÌ µ¥ÀÌÅÍ °øÀ¯¿Í °øµ¿ ÀÇ»ç°áÁ¤À» °¡´ÉÇÏ°Ô ÇÏ´Â ÅëÇÕ Ç÷§ÆûÀ» ¿ä±¸Çϸ鼭 ´ÙÁ÷Á¾°£ Çù·ÂÀÌ ½ÃÀåÀ» ´õ¿í Ȱ¼ºÈ­½Ã۰í ÀÖ½À´Ï´Ù. À¯ÀüÀÚ ¹× ºÐÀÚ ÇÁ·ÎÆÄÀϸµÀ» ÅëÇÑ °³ÀÎ ¸ÂÃãÇü ÀÇ·á·ÎÀÇ Àüȯµµ Ä¡·á °èȹÀ» Çü¼ºÇϰí ÀÖÀ¸¸ç, ÀÓ»óÀÇ´Â Ä¡·á ÇÁ·ÎÅäÄÝÀ» ÃÖÀûÈ­Çϱâ À§ÇØ È¯ÀÚº° µ¥ÀÌÅ͸¦ ÅëÇÕÇÒ ¼ö ÀÖ´Â ½Ã½ºÅÛÀ» ÇÊ¿ä·Î ÇÕ´Ï´Ù. ¶ÇÇÑ, Àúħ½ÀÀû Ä¡·á¿Í ¿Ü·¡ Ä¡·á°¡ °­Á¶µÇ¸é¼­ ÀÓ»ó ¿öÅ©Ç÷ο츦 °£¼ÒÈ­Çϰí ȯÀÚ Ã³¸®·®À» Çâ»ó½ÃŰ¸ç º¸´Ù È¿À²ÀûÀÌ°í »ç¿ëÀÚ Ä£È­ÀûÀÎ Ä¡·á °èȹ ½Ã½ºÅÛ °³¹ßÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÁøÈ­ÇÏ´Â ÀÓ»ó ¿ëµµ°ú ÃÖÁ¾ »ç¿ëÀÚÀÇ ¿ä±¸»çÇ×À¸·Î ÀÎÇØ Á¦Á¶¾÷ü´Â ÃֽŠÁ¾¾ç Ä¡·áÀÇ ¾ö°ÝÇÑ ±âÁØÀ» ÃæÁ·Çϱâ À§ÇØ ¹æ»ç¼± Ä¡·á °èȹ ½Ã½ºÅÛÀÇ ±â´É, Á¤È®¼º ¹× ÅëÇÕ ±â´ÉÀ» Áö¼ÓÀûÀ¸·Î Çâ»ó½ÃÄÑ¾ß ÇÕ´Ï´Ù.

±ÙÁ¢Ä¡·á °èȹ ½Ã½ºÅÛ »ê¾÷¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ±ÔÁ¦¿Í ½ÃÀå ¿ªÇÐÀº ¹«¾ùÀΰ¡?

±ÙÁ¢Ä¡·á °èȹ ½Ã½ºÅÛ »ê¾÷Àº Ä¡·áÀÇ Á¤È®¼º, ȯÀÚ ¾ÈÀü, ¾÷¹« È¿À²¼ºÀ» º¸ÀåÇÏ´Â ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í ¿ªµ¿ÀûÀÎ ½ÃÀå ¿ªÇп¡ Å©°Ô ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¹Ì±¹ FDA, À¯·´ CE, ±âŸ ±¹Á¦ º¸°Ç ´ç±¹°ú °°Àº ±ÔÁ¦ ±â°üÀº ¼ÒÇÁÆ®¿þ¾î ¼º´É, ¿ë·® Á¤È®µµ, µ¥ÀÌÅÍ º¸¾È¿¡ ´ëÇØ ¾ö°ÝÇÑ ±âÁØÀ» Àû¿ëÇϰí ÀÖÀ¸¸ç, Á¦Á¶¾÷ü´Â °­·ÂÇÑ Å×½ºÆ®, ÀÓ»ó °ËÁõ, ǰÁú º¸Áõ ÇÁ·ÎÅäÄÝ¿¡ ÅõÀÚÇØ¾ß ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦·Î ÀÎÇØ Ä¡·á °èȹ ½Ã½ºÅÛÀº Á¤È®ÇÑ ¹æ»ç¼±·®À» Á¦°øÇÒ »Ó¸¸ ¾Æ´Ï¶ó ȯÀÚÀÇ ¾ÈÀü°ú ÇÁ¶óÀ̹ö½Ã¿¡ ´ëÇÑ ¾ö°ÝÇÑ ¿ä±¸ »çÇ×À» ÁؼöÇØ¾ß ÇÕ´Ï´Ù. ½ÃÀå ¿ªÇÐÀº ¾Ï ¹ßº´·ü Áõ°¡, ¿µ»ó ±â¼úÀÇ ¹ßÀü, °³ÀÎ ¸ÂÃãÇü Ä¡·á ÇÁ·ÎÅäÄÝ·ÎÀÇ Àüȯ¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ÀüüÀûÀ¸·Î ÃÖ÷´Ü Ä¡·á °èȹ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. °æÀï ȯ°æÀº ±Þ¼ÓÇÑ ±â¼ú Çõ½ÅÀ¸·Î Ư¡Áö¾îÁö¸ç, ±â¾÷µéÀº µðÁöÅÐ Çõ½Å, Ŭ¶ó¿ìµå ±â¹Ý ¼Ö·ç¼Ç, AI ±â¹Ý ºÐ¼®¿¡ ÅõÀÚÇÏ¿© ½Ã½ºÅÛ ¼º´É°ú »ç¿ëÀÚ °æÇèÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÇ·áºñ »ó½Â°ú ÀÚ¿øÀÇ È¿À²Àû Ȱ¿ëÀÇ Çʿ伺 µî °æÁ¦Àû ¾Ð¹ÚÀ¸·Î ÀÎÇØ ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü´Â ¿öÅ©Ç÷ο츦 °£¼ÒÈ­Çϰí Ä¡·á °èȹ ½Ã°£À» ´ÜÃàÇÏ´Â °èȹ ½Ã½ºÅÛÀ» µµÀÔÇØ¾ß ÇÏ´Â »óȲ¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±â¼ú Á¦°ø¾÷ü, ¿¬±¸±â°ü, ÀÇ·á±â°üÀÇ Àü·«Àû Çù·ÂÀº Ä¡·á Á¦°ø Ç÷§Æû°ú ¿øÈ°ÇÏ°Ô ÅëÇÕµÇ¾î ¹æ»ç¼± Ä¡·áÀÇ ¿£µåÅõ¿£µå Á¤È®¼ºÀ» º¸ÀåÇÏ´Â Â÷¼¼´ë ½Ã½ºÅÛ °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦¿Í ½ÃÀå ¿ªÇÐÀº ±ÙÁ¢Ä¡·á °èȹ ½Ã½ºÅÛ »ê¾÷ÀÇ ¹Ì·¡¸¦ Çü¼ºÇϰí, »õ·Î¿î ±â¼úÀÌ ÃÖ°í ¼öÁØÀÇ À¯È¿¼º, ¾ÈÀü¼º, ÅëÇÕ¼ºÀ» ÃæÁ·Çϵµ·Ï º¸ÀåÇÕ´Ï´Ù.

±ÙÁ¢Ä¡·á °èȹ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù.

¹æ»ç¼± Ä¡·á °èȹ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀº ¿µ»ó ¹× ¼ÒÇÁÆ®¿þ¾î ¾Ë°í¸®ÁòÀÇ ±â¼ú Çõ½Å, Á¾¾çÇÐ ºÐ¾ßÀÇ ÀÓ»ó Àû¿ë È®´ë, Á¤È®Çϰí ȯÀÚ ¸ÂÃãÇü Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ±ÔÁ¦ ¹× ½ÃÀå ¾Ð·Â Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °íÇØ»óµµ À̹ÌÁö, µðÁöÅÐ ¸ðµ¨¸µ, AI ±â¹Ý ¿¹Ãø ºÐ¼®ÀÇ ¹ßÀüÀº º¸´Ù Á¤È®ÇÑ ¼±·® °è»ê°ú ÀûÀÀÇü Ä¡·á ÇÁ·ÎÅäÄÝÀ» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á Ä¡·á °èȹ¿¡ Çõ¸íÀ» ºÒ·¯ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¸ÂÃãÇü ÀÇ·á·ÎÀÇ Àüȯ°ú ÇÔ²² Ç×¾ÏÈ­Çпä¹ýÀ¸·Î È¿°úÀûÀ¸·Î Ä¡·áÇÒ ¼ö ÀÖ´Â ¾ÏÀÇ ¹ßº´·üÀÌ Áõ°¡Çϸ鼭 ÃÖÀûÀÇ Ä¡·á °á°ú¸¦ Á¦°øÇÏ´Â °íµµÈ­µÈ °èȹ ½Ã½ºÅÛÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¾ö°ÝÇÑ Ç°Áú °ü¸®, ȯÀÚ ¾ÈÀü ¹× µ¥ÀÌÅÍ º¸¾È¿¡ ´ëÇÑ ±ÔÁ¦ °­È­·Î ÀÎÇØ Á¦Á¶¾÷üµéÀº ±¹Á¦ Ç¥ÁØÀ» ÁؼöÇϰí ÀÓ»ó ¿öÅ©Ç÷οì¿ÍÀÇ ¿øÈ°ÇÑ ÅëÇÕÀ» ÃËÁøÇÏ´Â Â÷¼¼´ë ±â¼ú¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ŭ¶ó¿ìµå ±â¹Ý Ç÷§Æû°ú µðÁöÅÐ Çù¾÷ µµ±¸ÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Ä¡·á °èȹ ½Ã½ºÅÛÀÇ È®À强°ú Á¢±Ù¼ºÀÌ °­È­µÇ¾î ´ÙÁ÷Á¾ ÆÀÀÌ È¿À²ÀûÀ¸·Î Çù¾÷ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº Àü·«Àû ÆÄÆ®³Ê½Ê, Áö¼ÓÀûÀÎ R&D ÅõÀÚ, ½ÃÀå ÁÖµµÇü Çõ½Å°ú ÇÔ²² ±ÙÁ¢Ä¡·á °èȹ ½Ã½ºÅÛ ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀå°ú ÀÓ»óÀû È¿°ú Çâ»óÀ» À§ÇØ Àü ¼¼°èÀûÀ¸·Î ±ÙÁ¢Ä¡·á °èȹ ½Ã½ºÅÛ ½ÃÀåÀÇ Áö¼ÓÀûÀÎ È®ÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

±¸¼º ¿ä¼Ò À¯Çü(ÀÚµ¿ ÄÁÅõ¾î¸µ ¼ÒÇÁÆ®¿þ¾î, ¸ÖƼ ¸ð´Þ¸®Æ¼ ¼ÒÇÁÆ®¿þ¾î, PET/CT º¯Çü °¡´É ¼ÒÇÁÆ®¿þ¾î, DICOM-RT ¼ÒÇÁÆ®¿þ¾î); ±â¼ú(·ë ³» ¿µ»ó ÃÔ¿µ, 3D À̹ÌÁö À籸¼º, ±×·¡ÇÈ ÇÁ·Î¼¼¼­ À¯´ÖÀ» »ç¿ëÇÑ À̹ÌÁö µî·Ï)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå°ú °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Brachytherapy Treatment Planning Systems Market to Reach US$1.4 Billion by 2030

The global market for Brachytherapy Treatment Planning Systems estimated at US$887.1 Million in the year 2024, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 8.3% over the analysis period 2024-2030. Auto-Contouring Software, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$684.4 Million by the end of the analysis period. Growth in the Multi-Modality Software segment is estimated at 8.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$241.7 Million While China is Forecast to Grow at 13.2% CAGR

The Brachytherapy Treatment Planning Systems market in the U.S. is estimated at US$241.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$312.7 Million by the year 2030 trailing a CAGR of 13.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 8.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.

Global Brachytherapy Treatment Planning Systems Market - Key Trends & Drivers Summarized

What Are the Technological Innovations Transforming Brachytherapy Treatment Planning Systems?

The brachytherapy treatment planning systems market is experiencing a transformative phase driven by rapid technological innovations that are reshaping the precision and efficiency of cancer treatment planning. Advanced imaging technologies, including high-resolution CT, MRI, and PET scans, are being integrated into treatment planning systems to provide detailed, three-dimensional representations of tumor anatomy and surrounding tissues. This integration allows for more accurate dose calculations and spatial mapping, thereby improving the targeting accuracy of radioactive implants. The incorporation of sophisticated computer-aided design (CAD) and simulation software enables clinicians to model various treatment scenarios and optimize radiation delivery, reducing the risk of damage to healthy tissues. Innovations in software algorithms, powered by artificial intelligence (AI) and machine learning, are enhancing the automation of complex calculations, leading to faster and more precise treatment plans. Real-time data integration and adaptive planning tools allow for dynamic adjustments during therapy, ensuring that the treatment remains optimal even as tumor geometry changes. Enhanced user interfaces and visualization tools provide intuitive controls and comprehensive treatment data, facilitating better decision-making and streamlined workflows. These advancements are supported by cloud-based platforms that offer scalable processing power and secure data storage, enabling collaborative treatment planning across multidisciplinary teams. As treatment planning systems continue to evolve, the incorporation of predictive analytics and digital twins is further optimizing dosimetry, thus setting new benchmarks in personalized cancer therapy. This technological evolution is driving significant improvements in both treatment efficacy and patient safety, laying the groundwork for the next generation of brachytherapy solutions.

How Are Clinical Applications and End-User Requirements Shaping the Brachytherapy Treatment Planning Systems Market?

Clinical applications and evolving end-user requirements are fundamentally driving the expansion of brachytherapy treatment planning systems across oncology centers worldwide. With the increasing adoption of brachytherapy for the treatment of prostate, cervical, and breast cancers, there is a rising demand for systems that can deliver highly precise, customized treatment plans tailored to individual patient anatomy and tumor characteristics. Clinicians require tools that not only provide accurate dose calculations but also integrate seamlessly with imaging and delivery systems to facilitate real-time adjustments during therapy. The need for improved patient outcomes is pushing hospitals and cancer centers to invest in advanced planning systems that reduce treatment planning time while enhancing the accuracy of radiation delivery. Multidisciplinary collaboration is further fueling the market as radiation oncologists, medical physicists, and dosimetrists seek integrated platforms that enable data sharing and collaborative decision-making. The transition toward personalized medicine, driven by genetic and molecular profiling, is also shaping treatment planning, as clinicians require systems capable of incorporating patient-specific data to optimize therapy protocols. Furthermore, the growing emphasis on minimally invasive procedures and outpatient treatments is influencing the development of more efficient, user-friendly planning systems that streamline clinical workflows and improve patient throughput. These evolving clinical applications and end-user demands are compelling manufacturers to continually enhance the functionality, accuracy, and integration capabilities of brachytherapy treatment planning systems, ensuring that they meet the rigorous standards of modern oncology care.

What Regulatory and Market Dynamics Are Influencing the Brachytherapy Treatment Planning Systems Industry?

The brachytherapy treatment planning systems industry is significantly influenced by stringent regulatory frameworks and dynamic market forces that ensure treatment accuracy, patient safety, and operational efficiency. Regulatory bodies such as the U.S. FDA, European CE, and other international health authorities impose rigorous standards on software performance, dosimetric accuracy, and data security, compelling manufacturers to invest in robust testing, clinical validation, and quality assurance protocols. These regulatory mandates ensure that treatment planning systems not only deliver precise radiation doses but also adhere to strict patient safety and privacy requirements. Market dynamics are driven by the increasing prevalence of cancer, advancements in imaging technologies, and the shift toward personalized treatment protocols, which collectively drive the demand for state-of-the-art planning systems. The competitive landscape is characterized by rapid innovation, with companies investing in digital transformation, cloud-based solutions, and AI-driven analytics to enhance system performance and user experience. Economic pressures, such as rising healthcare costs and the need for efficient resource utilization, further compel healthcare providers to adopt planning systems that streamline workflows and reduce treatment planning times. Additionally, strategic collaborations between technology providers, research institutions, and healthcare organizations are facilitating the development of next-generation systems that integrate seamlessly with treatment delivery platforms, ensuring end-to-end precision in brachytherapy. These regulatory and market dynamics are shaping the future of the brachytherapy treatment planning systems industry, ensuring that new technologies meet the highest standards of efficacy, safety, and integration.

The Growth in the Brachytherapy Treatment Planning Systems Market Is Driven by Several Factors…

The growth in the Brachytherapy Treatment Planning Systems market is driven by several factors, including technological innovations in imaging and software algorithms, expanding clinical applications in oncology, and evolving regulatory and market pressures that demand precise, patient-specific treatment solutions. Advancements in high-resolution imaging, digital modeling, and AI-driven predictive analytics are revolutionizing treatment planning by enabling more accurate dose calculations and adaptive therapy protocols. The rising incidence of cancers that are effectively treated with brachytherapy, combined with a global shift toward personalized medicine, is fueling the need for sophisticated planning systems that deliver optimal therapeutic outcomes. Regulatory mandates for rigorous quality control, patient safety, and data security are driving manufacturers to invest in next-generation technologies that comply with international standards and facilitate seamless integration with clinical workflows. Furthermore, the increasing adoption of cloud-based platforms and digital collaboration tools is enhancing the scalability and accessibility of treatment planning systems, enabling multi-disciplinary teams to work together efficiently. These factors, along with strategic partnerships, continuous R&D investments, and market-driven innovation, are collectively propelling the Brachytherapy Treatment Planning Systems market toward sustained global expansion and enhanced clinical efficacy.

SCOPE OF STUDY:

The report analyzes the Brachytherapy Treatment Planning Systems market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component Type (Auto-Contouring Software, Multi-Modality Software, PET/CT Deformable Software, DICOM-RT Software); Technique (In-Room Imaging, 3D Image Reconstruction, Image Registration using Graphics Processor Unit)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â